A Phase 3 interventional study of Orelabrutinib and Placebo in Secondary Progressive Multiple Sclerosis, sponsored by Zenas BioPharma (USA), LLC. Recruiting at 96 sites in 20 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Zenas BioPharma (USA), LLC · Phase 3, Interventional, and Treatment
Hungary, Ukraine, Australia, Greece, Spain, Belgium, France, Germany, Romania
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States — 25 open to participants now, 38 under way, 9 of them phase 3. Multiple Sclerosis, Chronic Progressive · United States.
Among the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, this one is the 6th largest by planned enrollment of the 85 interventional ones that give a count, is one of 9 that started in 2026, is one of 20 in phase 3, reaches primary completion later than 32 of the 37 other live ones, and was the 98th registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →25 of the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States are open now. Recruiting first, the newest first:
University of Iowa · Sites in United States
Ages 45–70
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Zenas BioPharma (USA), LLC · Sites in United States, Australia, Bulgaria and 15 more countries
Ages 18–60
Tr1X, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 32 · Phase 3 22 · Phase 4 1
First in 2002; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 990 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 59 across the 85 interventional studies, 125 across the 20 observational. Of the 62 that completed or were terminated, 28 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 105 have an industry lead sponsor. The 10 most frequent:
Zenas BioPharma (USA), LLC is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Zenas BioPharma (USA), LLC has 2 studies filed under Multiple Sclerosis, Chronic Progressive — fewer than ten, so there is no comparison to draw.
10 of the studies in Multiple Sclerosis, Chronic Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07355387University of Illinois at ChicagoHome Based Functional Balance Intervention for Multiple Sclerosis | 2026-11-24 |
| NCT03109288National Institute of Allergy and Infectious Diseases (NIAID)Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) | 2027-01-01 |
| NCT07270120Ohio State UniversitySenolytics for Secondary Progressive MS | 2027-01-15 |
| NCT05122559Emmanuelle Waubant, MD PhDNeuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis | 2027-02 |
| NCT06384976Kyverna TherapeuticsKYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | 2027-04 |
Add all 10 to your calendar (.ics) → With an account.
Among the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
The study consists of the following periods:
All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Orelabrutinib PO daily
Drug: Orelabrutinib
Placebo PO daily
Drug: Placebo
Orelabrutinib orally
Placebo orally
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is \> 5.0
Time frame: Up to approximately 120 weeks
12 Week CDP
Time to onset of CDP events on EDSS, confirmed over at least 12 weeks
Time frame: Up to approximately 120 weeks
T2 lesions on MRI
The total number of new or enlarging T2 lesions on MRI scans of the brain
Time frame: Up to approximately 120 weeks
24-week CDP-9-hole Peg Test
Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks
Time frame: Up to approximately 120 weeks
24-week CDP-T25FWT
Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks
Time frame: Up to approximately 120 weeks
24-week CDI
Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is \> 5.0, confirmed over at least 24 weeks
Time frame: Up to approximately 120 weeks
24-week CDI-9HPT
Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks
Time frame: Up to approximately 120 weeks
24-week CDI-T25FWT
Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks
Time frame: Up to approximately 120 weeks
Symbol Digit Modalities Test
The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit
Time frame: Up to approximately 120 weeks
Annualized relapse rate
Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses
Time frame: Up to approximately 120 weeks
To evaluate the safety and tolerability of orelabrutinib
Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0);
Time frame: Up to approximately 120 weeks
Not enrolling at this site — choose another above.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 51 months after the start.
Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's planned 51 months is below that.
How these figures are worked out, and which studies are left out of them.
Hungary, Ukraine, Australia, Greece, Spain, Belgium, France, Germany, Romania
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orelabrutinib
Multiple Sclerosis, Chronic Progressive →
Zenas BioPharma (USA), LLC